Hansa Biopharma

Hansa Biopharma is a Lund-based clinical-stage biopharmaceutical company developing enzyme-based immunomodulatory treatments for transplantation and rare autoimmune conditions. Its lead product imlifidase (Idefirix) is approved in the EU for desensitization of highly sensitized kidney transplant patients, and the company is pursuing US FDA approval expected in 2026. Listed on Nasdaq Stockholm, Hansa Biopharma employs approximately 150 people following a restructuring in 2025 and is headquartered at Scheelevägen 22 in Lund.